index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

95

 

NOTICES

156

 

 

MOTS CLES

Pharmaco-Épidémiologie Psoriasis Anti-TNF Meta-Analysis Antibiotics Psoriatic arthritis Alcohol Apremilast Atrial fibrillation Anxiété Auto-Diagnostic Immune-related adverse events Stability Quality of life Placebo Epidemiology Ustekinumab Biomédicaments Auto-immune hepatitis Primary adrenal insufficiency Anti-Bacterial Agents Immune checkpoint inhibitors Etanercept Vigibase® Systematic review Dermatology Albinism Endocrine toxicity ArtThese Drug reaction Management Alitretinoin Biological Therapy Access to care Sipuleucel-T Cardio-oncology BTK protein Intensive care Antibiotic misuse Beta-lactam antibiotics Spondylitis COVID-19 Ankylosing spondylitis Ankylosing Biological therapy Arrhythmia Cardiotoxicity Anti-HCV Direct Acting Antivirals DAA Bacterial rhinosinusitis Drug survival Addiction Pharmacoepidemiology Antimicrobial resistance Glucocorticoids Azathioprine Apre-milast Infliximab ASDAS Immunotherapy Treatment Biosimilar Pharmaceuticals Adverse side effects Antimicrobials Aging Adolescent Antimicrobiens Biologic therapy Autoimmunity Burden Autoimmune diseases Anxiety Network meta-analysis Atopic dermatitis Arthritis Antibiotic resistance Biologics Angiotensin receptor blockers Bacterial Pregnancy Acute Myeloid Leukaemia AML Antimicrobial Stewardship Cardiomyopathy Abus d'antibiotiques Adalimumab Cancer Biomarkers Amyloidosis Pharmacovigilance Sacroiliitis Graft-versus-host disease Angiotensin-converting enzyme inhibitors Biologic drug Spondyloarthritis Biologic Axial spondyloarthritis Accelerometer Prostate cancer Méta-Analyse Ethics Anticancer drugs

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS